2011
Testicular Doses in Image-Guided Radiotherapy of Prostate Cancer
Deng J, Chen Z, Yu JB, Roberts KB, Peschel RE, Nath R. Testicular Doses in Image-Guided Radiotherapy of Prostate Cancer. International Journal Of Radiation Oncology • Biology • Physics 2011, 82: e39-e47. PMID: 21489702, DOI: 10.1016/j.ijrobp.2011.01.071.Peer-Reviewed Original ResearchConceptsImage-guided radiotherapyTesticular dosesFull-fan modeProstate cancerFemoral headLess doseCBCT scansHalf-fan modeProstate cancer patientsKilovoltage cone-beamCancer patientsIntensity-modulated radiotherapy (IMRT) treatmentKilovoltage CBCTSuperior-inferior directionCone beamDosesCBCT fieldProstate patientsRectumDoseProstateMore doseRadiotherapy treatmentPatientsRadiotherapy
2009
AAPM recommendations on dose prescription and reporting methods for permanent interstitial brachytherapy for prostate cancer: Report of Task Group 137
Nath R, Bice WS, Butler WM, Chen Z, Meigooni AS, Narayana V, Rivard MJ, Yu Y. AAPM recommendations on dose prescription and reporting methods for permanent interstitial brachytherapy for prostate cancer: Report of Task Group 137. Medical Physics 2009, 36: 5310-5322. PMID: 19994539, PMCID: PMC2776817, DOI: 10.1118/1.3246613.Peer-Reviewed Original ResearchConceptsBiological equivalent doseTumor volumeDose prescriptionStandard of careProstate cancer patientsPermanent interstitial brachytherapyAcute single dosesEffects of edemaCancer patientsSurgical traumaIntraoperative implantationSingle dosesClinical trialsProstate cancerRadiobiological modelsCurrent recommendationsInterstitial brachytherapyMore specific guidelinesRoutine patient treatmentsDifferent dose distributionsTreatment planPatient treatmentTarget volumeMost implantsDose distribution
1999
Long‐term complications with prostate implants: Iodine‐125 vs. palladium‐103
Peschel R, Chen Z, Roberts K, Nath R. Long‐term complications with prostate implants: Iodine‐125 vs. palladium‐103. International Journal Of Cancer 1999, 7: 278-288. PMID: 10580897, DOI: 10.1002/(sici)1520-6823(1999)7:5<278::aid-roi3>3.0.co;2-3.Peer-Reviewed Original ResearchMeSH KeywordsActuarial AnalysisBrachytherapyCell DeathFollow-Up StudiesForecastingHumansIodine RadioisotopesLongitudinal StudiesMaleModels, BiologicalNeoplasm StagingPalladiumProbabilityProstatic NeoplasmsRadioisotopesRadiopharmaceuticalsRadiotherapy DosageRelative Biological EffectivenessRetrospective StudiesTreatment OutcomeConceptsLong-term complicationsMinimum tumor dosesComplication ratePd-103Lower overall complication ratePalladium-103Long-term complication rateIodine-125Overall complication rateHigh complication rateProstate cancer patientsProstate implantsActuarial probabilityGrade IIILog10 cell killCancer patientsVs. 6Tumor dosesClinical practiceCell killProstate cancer brachytherapyEffective doseNormal tissuesPatientsTissue beds
1998
Correlation of medical dosimetry quality indicators to the local tumor control in patients with prostate cancer treated with iodine‐125 interstitial implants
Nath R, Roberts K, Ng M, Peschel R, Chen Z. Correlation of medical dosimetry quality indicators to the local tumor control in patients with prostate cancer treated with iodine‐125 interstitial implants. Medical Physics 1998, 25: 2293-2307. PMID: 9874821, DOI: 10.1118/1.598440.Peer-Reviewed Original ResearchConceptsSurvival rateProstate cancerInterstitial implantsLocal recurrence-free survival rateRecurrence-free survival ratesLocal control rateLocal tumor controlExcellent clinical resultsProstate cancer patientsUnfavorable groupClinical efficacyCancer patientsControl rateTumor controlClinical resultsFavorable groupDose coveragePatientsDosimetric parametersDosimetry parametersIsodose surfaceSignificant differencesVirginia studyUnfavorable parametersCancer